Retrospective analysis of percutaneous transluminal coronary angioplasty and coronary stenting / 中华医学杂志(英文版)
Chinese Medical Journal
;
(24): 483-486, 2002.
Article
in English
| WPRIM
| ID: wpr-302271
ABSTRACT
<p><b>OBJECTIVE</b>To examine long-term efficacy of percutaneous transluminal coronary angioplasty (PTCA), coronary stenting and to assess the factors affecting its efficacy.</p><p><b>METHODS</b>A total of 790 patients who underwent successful PTCA and PTCA + stent in this hospital were followed by direct interview or letter. The rate of follow-up was 84.2% and the period of follow-up was 0.9 - 12.7 (3.5 +/- 2.4) years.</p><p><b>RESULTS</b>During follow-up, 4 (0.5%) patients died, 22 (2.8%) had nonfatal acute myocardial infarction, 10 (1.3%) had coronary artery bypass surgery, and 98 (12.4%) had repeat PTCA. The rate of recurrent angina pectoris was 31.1%. The cardiac event-free survival rate calculated by the Kaplan-Meier method was 88.2% at 1 year and 80.6% at 12.7 years. Cox regression analysis showed that there was a positive correlation between AMI history, stent implantation and the risk of cardiac events, and there was a negative correlation between the number of diseased arteries and the risk of cardiac events. Compared to the PTCA group, patients with PTCA + stent had significantly lower rates of total cardiac events.</p><p><b>CONCLUSION</b>The long-term efficacy of PTCA, especially PTCA + stent in Chinese patients was very satisfactory, suggesting that PTCA + stent therapy should be the major treatment for revascularization in patients with coronary heart disease.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Therapeutics
/
Angioplasty, Balloon, Coronary
/
Stents
/
Multivariate Analysis
/
Survival Rate
/
Retrospective Studies
/
Follow-Up Studies
/
Mortality
/
Treatment Outcome
/
Coronary Stenosis
Type of study:
Observational study
/
Prognostic study
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
Language:
English
Journal:
Chinese Medical Journal
Year:
2002
Type:
Article
Similar
MEDLINE
...
LILACS
LIS